Home » News: Report: Novartis Wants More Savings In Production, Marketing
News: Report: Novartis Wants More Savings In Production, Marketing
Pharmaceuticals company Novartis AG is targeting further savings in marketing and production, Chief Executive Joe Jimenez tells Swiss newspaper Handelszeitung.
"We have spent too much money on marketing and selling our drugs," Jimenez says in an interview to be published Thursday.
Novartis has already reduced its spending, but Jimenez said, "We can save even more, even if we grow. This business revolves around science, not around marketing."
Further savings are also planned in the production area, Jimenez says, which could mean plant closures.
"We have 83 factories and we only use about 50% to full capacity--that isn't good," Jimenez says.
The company's research and development budget would remain intact, and could even be increased in the next five years, the CEO says.
Jimenez says he is optimistic about the future.
Merck Stops Development of Parkinsonís DrugFrom Bloomberg
Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesnít work
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
- All news »